metabisulphite, 6 adenosine 5′-monophosphate (AMP), 7 and bradykinin. 8 Although the mechBackground -Inhaled frusemide exerts a protective effect against broncho-anisms underlying the protective effects of this drug against these different forms of proconstriction induced by several indirect stimuli in asthma which could be due to vocation in asthma are not yet clear, an inhibitory effect on airway nerves has been interference of airway nerves. A randomised, double blind, placebo controlled suggested. In support of this, inhaled frusemide has been shown to inhibit the cough response study was performed to investigate the effect of the potent loop diuretic, fru-induced by low chloride aerosols 9 and to produce dose-dependent inhibition of the consemide, administered by inhalation on the bronchoconstrictor response to neuro-tractile response of airways smooth muscle induced by the stimulation of cholinergic and kinin A (NKA) and histamine in 11 asthmatic subjects.
Methods -Subjects attended the laboratory on four separate occasions to receive
The peptide tachykinin, neurokinin A (NKA), exhibits a range of features which may nebulised frusemide (40 mg) or matched placebo 10 minutes prior to bronchial chal-be relevant to the pathophysiology of asthma, including contraction of airway smooth muscle, lenge with NKA and histamine in a randomised, double blind order. Changes in increased vascular permeability, mucus secretion, and activation of cholinergic neuroairway calibre were followed as forced expiratory volume in one second (FEV 1 ) and transmission. 11 12 Immunocytochemical studies have demonstrated the presence of NKA and its responsiveness to the agonists was expressed as the provocative concentration related receptors within the human airways. 13 14 When administered by inhalation to asthmatic causing a 20% fall in FEV 1 from baseline (PC 20 ).
subjects NKA elicits dose-related bronchoconstriction, with the asthmatic subjects being Results -Compared with placebo, inhaled frusemide reduced the airway responsive-more responsive than normal individuals. [15] [16] [17] [18] [19] The mode of action by which NKA elicits ness to NKA in all the subjects studied, the geometric mean (range) values for bronchoconstriction in asthma is not well understood. The bronchoconstrictor effect of PC 20 NKA increasing significantly (p<0.001) from 130.3 (35.8-378.8) to 419.9 nebulised NKA in asthmatic patients is inhibited by prior treatment with nedocromil (126.5-1000) g/ml after placebo and frusemide, respectively. Moreover, a small sodium, 17 20 suggesting that this response may be evoked indirectly rather than through direct but significant change in airway responsiveness to histamine was recorded stimulation of airway smooth muscle. In addition, there is recent evidence for an action of after frusemide, their geometric mean (range) PC 20 values being 0.58 (0.12-3.80) NKA in eliciting bronchoconstriction through activation of cholinergic pathways. 21 and 1.04 (0.28-4.33) mg/ml after placebo and frusemide, respectively. We have therefore investigated the effect of prior administration of frusemide, given by Conclusions -The decrease in airway responsiveness to NKA after administration inhalation, on the airways response of asthmatic subjects to NKA and to histamine which was cat fur, dog hair). At the beginning of the study Phase 1 Subjects attended the laboratory on two sepall subjects were asymptomatic with a baseline forced expiratory volume in one second (FEV 1 ) arate occasions, at least 72 hours apart, to undertake concentration-response studies with of >70% of their predicted values. None had received oral or topical steroids, theophylline, inhaled histamine and NKA in the absence of any drug treatment. antihistamines, or sodium cromoglycate within the preceding four weeks. Inhaled bronchoOn the first occasion, after 15 minutes rest, three baseline measurements of FEV 1 were dilators were discontinued for at least eight hours before each visit to the laboratory. Sub-made at intervals of three minutes followed by inhalation of 0.9% sodium chloride and further jects were not studied within four weeks of an upper respiratory tract infection or ex-FEV 1 measurements were repeated at one and three minutes. Provided FEV 1 had not fallen acerbation of their asthma and all visits to the laboratory were carried out at the same time by more than 10% of the baseline value, a histamine concentration-response study was of day and outside the pollen season.
The study was approved by the ethical sub-carried out. After administration of each histamine concentration FEV 1 was measured at committee of the Department of Respiratory Diseases (University of Catania) and all sub-one and three minutes. Increasing doubling concentrations of histamine were inhaled at jects gave their informed consent.
five minute intervals until FEV 1 had fallen by more than 20% of the post-saline baseline value. The fall in FEV 1 following each con-  centration of agonist was expressed as a perAirway calibre was recorded before and during centage of the higher of the two post-saline the provocation as FEV 1 using a dry wedge baseline FEV 1 recordings. The percentage fall spirometer (Vitalograph, Buckinghamshire, in FEV 1 was plotted against the cumulative UK), the better of the two consecutive measconcentration of agonist on a logarithmic scale urements being used for analysis. and the provocation concentration required to Histamine (Sigma Chemical Co, St Louis, produce a 20% decrease in FEV 1 from the postMissouri, USA) and NKA (Peninsula Laboratsaline baseline value (PC 20 ) was determined by ories Ltd) were made up in 0.9% sodium linear interpolation. On the second occasion a chloride (1% albumin solution) to produce a bronchial provocation test with inhaled NKA range of increasing doubling concentrations of was undertaken in a similar manner to that 0.03-16.00 mg/ml and 3.9-500 g/ml, redescribed for histamine. FEV 1 measurements spectively. The aqueous solutions were adwere recorded one and three minutes after ministered as aerosols generated from a starting inhalation of each concentration of NKA and volume of 3 ml in a disposable Inspiron minithe corresponding PC 20 FEV 1 values derived. nebuliser (C R Bard International, Sunderland, UK) driven by compressed air at 8 l/min. Under these conditions the nebuliser had an output of 0.48 ml/min and generated an aerosol with Phase 2 a mass median particle diameter of 4.7 m.
22
Subjects attended the laboratory on four sepWearing a nose clip, subjects inhaled the aero-arate occasions, at least four days apart, to solised solutions in five breaths from end-tidal undertake concentration-response studies with volume to full inspiratory capacity via a mouth-histamine and NKA after receiving nebulised piece as described by Chai et al. 23 Subjects were frusemide (Lasix, Hoechst, Frankfurt AM trained to take three seconds to reach full Main, Germany) or matched placebo adinspiratory capacity.
ministered double blind and in random order 10 minutes before challenge. The dosage of inhaled frusemide used in the present study and the timing of administration before bronchial   The study consisted of two distinct phases.
challenge were chosen on the basis of previous group.bmj.com on June 23, 2017 -Published by http://thorax.bmj.com/ Downloaded from studies. 7 8 Both the active and placebo solutions were freshly prepared by an independent investigator on the basis of a randomised code and then returned to the conducting physician to administer to the attending subject. On each occasion, after 15 minutes rest, three baseline measurements of FEV 1 were made at intervals of three minutes followed by inhalation of nebulised frusemide (10 mg/ml, 4 ml) or nebulised vehicle placebo consisting of 0.9% sodium chloride adjusted to the same pH and tonicity tidal breathing over 7-9 minutes. The same nebuliser was used for all studies on all subjects. Further FEV 1 measurements were repeated at one, five, and 10 minutes after drug/placebo inhalation and dose-response studies with in-linear regression analysis of their log-transformed PC 20 values. Linear regression analysis creasing concentrations of histamine and NKA were carried out in a similar manner to that was also used to evaluate any relationship between the concentration ratios after the drug described in phase 1.
and the airway responses to histamine and NKA.   Results are expressed as mean (SE) unless otherwise stated and p values of <0.05 were Results
There was no significant difference in mean accepted as the minimum level of statistical significance. Baseline values of FEV 1 before (SE) baseline values of FEV 1 between any of the study days, with values ranging from 2.37 and after treatment were compared between and within study days by two-factor analysis of (0.19) l to 2.44 (0.18) l. Administration of frusemide did not cause any change in FEV 1 variance (ANOVA).
After nebulised frusemide a 20% fall in FEV 1 from baseline on either NKA or histamine study days. Mean values of FEV 1 following was not obtained in five subjects (nos 1-4 and 7) at the highest concentration of NKA administration of frusemide were not significantly different from those after placebo administered, and therefore a minimal estimate was obtained by calculating the cumulative when compared at all time points.
Inhaled histamine and NKA produced con-PC 20 on the next doubling concentration beyond the highest administered. Because of these centration-related falls in FEV 1 When compared with placebo, inhaled frusemide had a significant protective effect Concentration ratios for the effect of frusemide against bronchoprovocation with each against the fall in FEV 1 produced by NKA.
Frusemide produced a displacement of the agonist were calculated individually by dividing the PC 20 value obtained after the active drug NKA concentration-response curve to the right in all the subjects studied. For these subjects by that obtained after placebo and compared using the Wilcoxon's signed rank test. The the geometric mean (range) PC 20 NKA values increased 3.5-fold from 130.3 (35.8-378.8) g/ relationship between the airway responses to histamine and NKA was tested by least squares ml to 419.9 (126.5-1000) g/ml after placebo and frusemide, respectively (p<0.01; fig 1, by increasing the availability for arachidonic haled NKA causes dose-related bronchoconstriction in asthmatic subjects. [15] [16] [17] [18] [19] We have acid 32 and enhances the urinary excretion of PGI 2 .
33 Since the inhibitory effect of loop dialso shown that frusemide administered by inhalation elicits protection of the airways uretics on nerve activation in human airways in vitro is related to the release of endogenous against bronchoconstriction provoked by NKA in all the asthmatic subjects studied. In ad-cyclooxygenase products from the epithelium, 26 it is suggested that frusemide may afford airway dition, we have shown a small but significant change in airway responsiveness to histamine protection by releasing epithelium derived PGE 2 and PGI 2 , both of which are potent following frusemide exposure. The protection afforded by frusemide was twice as great against functional antagonists. Other in vitro experiments in the guinea pig trachea also suggest NKA as against histamine, which suggests involvement of several mechanisms.
an influence of inhibitory prostaglandins. 34 In addition, PGE 2 has been shown to inhibit airThe approximately 3.5-fold displacement of the concentration-response curves to the right way neurotransmission in human bronchial preparations. 35 Recent data by Pavord et al 36 with NKA is similar to that reported with other indirectly acting bronchoconstrictor stimuli and by us 37 support the view that the prevention of bronchoconstrictor stimuli by loop diuretics and is similar to that observed after disodium cromoglycate or nedocromil sodium. In ad-in human airways may be due to the local production of inhibitory prostaglandins. Thus, dition, the observation that inhaled frusemide and disodium cromoglycate/nedocromil so-the inhibitory action of inhaled frusemide against NKA-induced bronchoconstriction is dium have little or no significant protective effect against methacholine-induced broncho-likely to be due to a suppressive action on the activation of neural pathways or to the local constriction in asthma 5-7 24 suggests that these drugs have indirect effects. There is now con-production of inhibitory prostaglandins with functional antagonistic effects. siderable evidence to support the hypothesis that frusemide has an inhibitory effect on neural
In this study we have also shown a small but significant effect of frusemide against hispathways in the airways. Frusemide has been shown to inhibit the cough response induced tamine-induced bronchoconstriction. Although this finding is in keeping with the data by low chloride solutions in dogs 25 and normal volunteers, 9 and both frusemide and bumetan-reported by Vaghi et al, 38 two previous studies failed to show any significant effect of frusemide ide produce dose-dependent inhibition of the contractile response of airways smooth muscle on histamine responses in both adult and paediatric asthmatic subjects. 39 40 There may be induced by stimulation of cholinergic and noncholinergic non-adrenergic nerves in guinea factors in the characteristics of these patients which affects their response to frusemide. The pigs. 10 Similarly, Verleden et al 26 have recently shown that loop diuretics elicit a dose-de-asthmatic subjects studied in the present investigation differ from those in the studies of pendent inhibition of cholinergic neurotransmission in human airways in vitro, possibly O'Connor et al 39 and Mochizuki et al 40 for having a considerably higher degree of bronvia an action on ion channels located on these nerves. Although the bronchoconstrictor ac-chial hyperresponsiveness. Moreover, Mochizuki et al found that inhaled frusemide tivity of NKA is markedly inhibited by nedocromil sodium, 17 20 the selective histamine H 1 afforded protection against bronchoconstriction only in the child with the highest degree receptor antagonist, terfenadine, does not appear to protect against NKA-induced bron-of bronchial hyperresponsiveness. Bronchial hyperresponsiveness correlates with the extent choconstriction. 27 Furthermore, anticholinergic blockade also affords protection against of epithelial damage in human asthma. Damaged airway epithelium may alter the pharthis agonist. 21 These findings, together with the results of the present investigation, suggest that macokinetic profile of inhaled loop diuretics, thus changing their local pharmacodynamic excitation of neural pathways may underlie NKA responses in human asthma. However, activity. It is therefore possible that higher drug 
